The Need for Psychedelic-Assisted Therapy in the Black Community and the Burdens of its Provision

The paper opens by situating psychedelic medicine — entheogens that produce non-ordinary states of consciousness — as a re-emerging therapeutic field with particular promise for trauma-related disorders such as post-traumatic stress disorder (PTSD). It notes that MDMA-assisted psychotherapy has progressed to late-stage clinical development (FDA "breakthrough therapy" designation in 2017 and Phase III trials), and that psychedelics can attenuate the fear-driven reactivity that perpetuates traumatic symptoms. The authors use PTSD as a model indication because of its stronger empirical base, while emphasising that race-based or racial trauma is a related and under-researched phenomenon that disproportionately affects Black, Indigenous and other People of Colour (BIPOC). Norrholm and colleagues set out to describe the historical and contemporary landscape connecting psychedelic-assisted therapy with the needs of Black communities, to document barriers to access and provision, and to propose pathways to more culturally competent and equitable delivery. They foreground racial trauma experienced by Black Americans, review physiological and psychological sequelae, survey the emerging clinical evidence for entheogens (particularly MDMA and psilocybin), and discuss systemic, clinical training, and community-level challenges and solutions for expanding access in BIPOC populations. A positionality statement clarifies that the authors include Black and White researchers with lived and clinical experience relevant to the topic, and that this perspective shapes the paper's aims and recommendations.

The extracted text does not present a formal Methods section or describe a systematic search strategy. Rather, the paper is a narrative, integrative review and perspective piece that synthesises historical accounts, empirical literature, trial reports, case studies, and the authors' own observations and interviews. It includes a declared positionality statement describing the racial identities and clinical/research backgrounds of the authors, which the authors use to contextualise their analysis. Content is organised thematically: historical and political context of psychedelic research and drug policy, prevalence and mechanisms of race-based trauma and PTSD, physiological and neurobiological consequences of chronic racial stressors, existing clinical evidence for psychedelics and related interventions, examples of clinical training and implementation efforts (including a post-hoc analysis of a MAPS training event), and recommendations for improving recruitment, training, and service delivery for BIPOC communities. The paper draws on published reviews and individual studies (including naturalistic and clinical reports, a ketamine case study, and early MDMA-assisted therapy experiences) and integrates descriptions of community organisations and clinical sites pursuing expanded access. Because no prespecified inclusion/exclusion criteria, database list, search dates, or formal quality assessment are reported in the extracted text, this work should be read as a critical, narrative overview rather than a systematic review.

Across the reviewed material, the authors report several convergent findings and observations. First, racial trauma is framed as both discrete traumatic events and a cumulative psychological injury caused by repeated exposure to racism, microaggressions, and structural violence; Black people in the US and Canada report higher rates of PTSD and pervasive race-based stressors. Physiologically, chronic racial stress is linked to dysregulation of the hypothalamic–pituitary–adrenal axis (elevated cortisol and catecholamines), altered neurotransmitter systems, changes in brain morphology and brainwave patterns, and downstream cardiovascular and metabolic morbidities. Second, the therapeutic potential of psychedelics is summarised: MDMA-assisted psychotherapy has demonstrated large effects for PTSD in clinical trials and received FDA "breakthrough" designation; three administrations of MDMA in trial protocols produced substantially greater benefit than long-term SSRI treatment according to the authors' synthesis. Other compounds and approaches (psilocybin, LSD, ayahuasca, and ketamine-assisted protocols) are noted as showing promising outcomes in at least 14 controlled or well-designed studies for mood and trauma-related disorders and in naturalistic reports for race-based trauma. The authors reference a ketamine-integrated, culturally informed outpatient intervention that yielded sustained symptom reductions in a single-case report. Third, substantial disparities in diagnosis, treatment and workforce representation are documented: Black physicians represent only 2% of US psychiatrists; the US psychology workforce is reported as 4% Black; of roughly 6,000 annual doctoral clinical psychology graduates, about 10% (approximately 300) are Black. The literature reviewed indicates differential diagnostic patterns (overdiagnosis of psychotic disorders and underdiagnosis of mood/anxiety disorders among Black patients), lower likelihood of receiving guideline treatments or disability awards, and lower access to care post-diagnosis among Black veterans. The authors also note that psychedelics use is statistically lowest among Black Americans and that cultural stigma and fears about legal consequences suppress uptake. Fourth, experiential and implementation challenges are highlighted. Accounts from early volunteer MDMA experiences include both healing narratives and harms: one Black participant reported a microaggression from co-therapists that exacerbated distress and required protracted integration work. A MAPS-funded training for BIPOC clinicians is described as having failed to share power and protect participants appropriately; the training did not adequately prepare White trainers to manage race-related trauma and some participants felt unsafe, leading to an incomplete certification outcome. Finally, the authors identify nascent community and clinical responses: a small number of expanded-access sites and community organisations (for example, Sage Institute, SoundMind Center, and Behavioural Wellness Clinic) are preparing culturally responsive programs and some clinicians are enrolling for MAPS training to provide MDMA-assisted therapy in underserved populations.

Norrholm and colleagues interpret their synthesis as evidence of a pressing need to make psychedelic-assisted therapies accessible and culturally competent for Black communities, while cautioning that poorly prepared provision risks harm. They argue that psychedelics have mechanistic plausibility and emerging empirical support for alleviating trauma-related symptoms, and therefore could be an important adjunct for racial trauma—provided delivery is embedded within culturally informed, trauma-sensitive therapeutic frameworks. The paper situates the current disparities in access and outcomes within a broader historical and political context: punitive drug policies (for example, the Nixon-era War on Drugs and subsequent legislation) and documented research abuses have contributed to mistrust, underrepresentation in research, and legal risks that discourage engagement with psychedelic medicine among Black people. Clinically, implicit bias, differential diagnostic patterns, and a dearth of Black clinicians are seen as structural barriers that can translate into misdiagnosis, undertreatment, and iatrogenic harm during psychedelic-assisted sessions. Key limitations and uncertainties are acknowledged by the authors: there are no manualised psychedelic protocols specifically developed and trialled for race-based trauma; the literature on psychedelics for racial trauma is limited and includes naturalistic reports and a small number of case studies rather than large, diverse randomised trials. The extracted text does not present new empirical trial data from the authors themselves; rather, it synthesises prior findings and experiential reports. The authors also note implementation failures in training programmes (for example, the MAPS training event) as evidence that existing certification and educational pathways are insufficiently prepared to meet BIPOC needs. In terms of implications, the authors recommend accelerated and deliberate efforts to increase BIPOC participation at multiple levels: recruit and retain BIPOC participants in clinical research; expand culturally competent training for facilitators and ensure power-sharing with experienced people of colour in programme design and delivery; forge partnerships between predominantly White psychedelic programmes and Historically Black Colleges and Universities to build workforce capacity; support community organisations that centre BIPOC voices and provide outreach and harm-reduction education; and expand access pathways such as MAPS' Expanded Access programmes at culturally responsive clinical sites. These steps are framed as necessary to both reduce harm and to enable therapeutic benefit for communities disproportionately affected by racial trauma.

The authors conclude that racial trauma is a widespread, under-treated cause of psychological and physiological harm among Black people, and that psychedelic-assisted therapy holds significant promise as a treatment adjunct. However, they emphasise that clinical benefit is not guaranteed and may be outweighed by harm if therapists and treatment systems lack specific training in race-based trauma and cultural competence. To mitigate these risks and to realise therapeutic potential, the paper calls for explicit inclusion of BIPOC medical professionals and psychology departments—particularly at HBCUs—in the development, testing, delivery and commercialisation of psychedelic medicines. Healing in BIPOC communities, the authors argue, will depend on such collaborative, well-resourced, and culturally grounded efforts.